About M4IVDGet in touch with us
The Manufacturing for In Vitro Diagnostics (M4IVD) was founded in 2019 to form an industry and research alliance that is focused on the development and pilot manufacturing for In-Vitro Diagnostics (IVD) products, including Point-of-Care (POC) devices, under a GMP quality management system and ISO 13485.
With many small to medium sized Swiss life science companies that are active in the research and development of biomarkers, M4IVD addresses an important gap in the technology transfer infrastructure in Switzerland. Integrating expertise and technologies from various partners, M4IVD offers a platform that helps companies to successfully accelerate the development and pilot production of IVD tests for companion diagnostics or personal health.
MEMBERS OF THE ASSOCIATION
M4IVD has generated great momentum in the exchange and integration of knowledge and experiences from various partners. Founded in 2019 by 5 industrial, 6 research, and 2 public partners, the alliance is growing as work progresses. As such, the whole chain from research to commercialization is covered.
A significant part of the M4IVD overall budget is provided by our industrial partners.
INNOVATION THROUGH COLLABORATION
M4IVD successfully brought together experts from academia, healthcare and industry to meet current innovation challenges in the field of IVD.
M4IVD supports Swiss TPH in obtaining a grant from BRCCH for combating COVID-19
One of the 11 research projects that got selected and received funding through Fast Track Call for Acute Global Health Challenges (FTC) initiative by the Botnar Research Centre for Child Health (BRCCH), was submitted by Swiss TPH with the support from M4IVD.
The FTC is an Emergency Response to COVID-19 and the unprecedented global health challenges stemming from the pandemic, for which Fondation Botnar commited CHF 20 million to international research efforts. Within the Diagnostics area the project of Swiss TPH received funding to develop a simple, low-cost device that can detect antibodies against SARS-CoV-2 by using saliva. The project seeks to identify individuals who have been previously infected with SARS-CoV-2 and to provide valuable insights into the variations in the immune response to COVID-19.
During pandemic isolations Covid-19 immunity testing is critical to allow people who have immunity to return to social life and work, in particular for critical positions, such as health workers. In contrast to other immunity tests, which are all blood based, the Consortium proposed to develop an easy-to-handle saliva sampling test to be used at home (self-testing). In pandemic situations, home testing is critical to prevent the spreading of infections when attending pharmacies and physician offices.Link to project
Swiss Tropical and Public Health Institute
University of Basel
Centre Suisse d’Electronique et de Microtechnique (CSEM)
University of Applied Sciences and of Arts Northwestern Switzerland
Effectum Medical AG
GET IN TOUCH WITH US
We look forward to hearing from you.